Your browser doesn't support javascript.
loading
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.
Hayakawa, F; Sakura, T; Yujiri, T; Kondo, E; Fujimaki, K; Sasaki, O; Miyatake, J; Handa, H; Ueda, Y; Aoyama, Y; Takada, S; Tanaka, Y; Usui, N; Miyawaki, S; Suenobu, S; Horibe, K; Kiyoi, H; Ohnishi, K; Miyazaki, Y; Ohtake, S; Kobayashi, Y; Matsuo, K; Naoe, T.
Affiliation
  • Hayakawa F; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Sakura T; Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Yujiri T; Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
  • Kondo E; Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Fujimaki K; Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan.
  • Sasaki O; Department of Internal Medicine, Miyagi Cancer Center, Natori, Japan.
  • Miyatake J; Department of Hematology and Rheumatology, Kinki University Faculty of Medicine, Osaka-sayama, Japan.
  • Handa H; Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Ueda Y; Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Aoyama Y; Department of Internal Medicine, Seichoukai Fuchu Hospital, Izumi, Japan.
  • Takada S; Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Tanaka Y; Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
  • Usui N; The Jikei University School of Medicine, Tokyo, Japan.
  • Miyawaki S; Division of Hematology, Tokyo Metropolitan Otsuka Hospital, Tokyo, Japan.
  • Suenobu S; Department of Pediatrics and Child Neurology, Oita University Faculty of Medicine, Oita, Japan.
  • Horibe K; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Kiyoi H; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Ohnishi K; Oncology Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Miyazaki Y; Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Ohtake S; Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
  • Kobayashi Y; Department of Hematology and Oncology, National Cancer Center Hospital, National Cancer Center, Tokyo, Japan.
  • Matsuo K; Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.
  • Naoe T; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Blood Cancer J ; 4: e252, 2014 Oct 17.
Article in En | MEDLINE | ID: mdl-25325302
ABSTRACT
The superiority of the pediatric protocol for adolescents with acute lymphoblastic leukemia (ALL) has already been demonstrated, however, its efficacy in young adults remains unclear. The ALL202-U protocol was conducted to examine the efficacy and feasibility of a pediatric protocol in adolescents and young adults (AYAs) with BCR-ABL-negative ALL. Patients aged 15-24 years (n=139) were treated with the same protocol used for pediatric B-ALL. The primary objective of this study was to assess the disease-free survival (DFS) rate and its secondary aims were to assess toxicity, the complete remission (CR) rate and the overall survival (OS) rate. The CR rate was 94%. The 5-year DFS and OS rates were 67% (95% confidence interval (CI) 58-75%) and 73% (95% CI 64-80%), respectively. Severe adverse events were observed at a frequency that was similar to or lower than that in children treated with the same protocol. Only insufficient maintenance therapy significantly worsened the DFS (hazard ratio 5.60, P<0.001). These results indicate that this protocol may be a feasible and highly effective treatment for AYA with BCR-ABL-negative ALL.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Asia Language: En Journal: Blood Cancer J Year: 2014 Document type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Asia Language: En Journal: Blood Cancer J Year: 2014 Document type: Article Affiliation country: Japan